更昔洛韦联合施保利通治疗巨细胞病毒肝炎疗效观察  

Therapeutic effects of ganciclovir combined with Esberitox N for cytomegalovirus hepatitis in infants

作　　者：李华[1] 

机构地区：[1]三峡大学仁和医院儿科,湖北宜昌443001

出　　处：《中国现代医生》2016年第3期94-96,共3页China Modern Doctor

摘　　要：目的探讨更昔洛韦联合施保利通治疗婴儿巨细胞病毒（CMV）肝炎的临床疗效。方法选取2012年5月～2014年5月我科收治的CMV肝炎患儿62例并将其随机分为两组：治疗组予更昔洛韦联合施保利通治疗,对照组单用更昔洛韦抗病毒治疗。观察对比两组患儿治疗前后症状体征、肝功能、血CMV-IgM、尿CMV-DNA结果。结果两组CMV肝炎患儿经治疗后,治疗组总有效率89.3%,高于对照组的61.8%,差异有统计学意义（P〈0.05）;治疗组患儿治疗后ALT、TBIL、DBIL明显下降,与对照组比较差异均有统计学意义（P〈0.05）;治疗组血CMV-IgM、尿CMV-DNA总转阴率82.1%,高于对照组的42.6%,差异有统计学意义（P〈0.05）。结论更昔洛韦联合施保利通治疗CMV能更好地改善肝功能,促进病毒转阴,疗效确切,未见明显不良反应,并且该药口感好,具有临床推广价值。Objective To observe the clinical efficacy of ganciclovir combined with for Esberitox N for cytomegalovirus hepatitis in infants. Methods A total of 62 hospital inpatients with cytomegalovirus hepatitis from May 2012 to May2014 in our department were selected and randomly divided into two groups. The treated group was received ganciclovir and Esberitox N, and the control group was received only ganciclovir. Children＇s detailed information,including symptoms,signs,testing results of liver functions, serum CMV-IgM and urine CMV-DNA were recorded before and after the treatment. Results In the treatment group the total effectiveness was 89.3%, far higher than 61.8% in the control group,there was a significant difference between the two groups（P〈0.05）. ALT、TBIL and DBIL of the treatment group was significantly lower the control group after treatment（P〈0.05）. The Negative rate of the serum CMV-IgM and the urine CMV-DNA In the the treatment group were superior to that of control group, there was a significant difference between the two groups（P〈0.05）. Conclusion Treating cytomegalovirus hepatitis in infant with ganciclovir and Esberitox N is evidently effective,and is favorably recommended for clinical use.

关 键 词：巨细胞病毒 肝炎 更昔洛韦 施保利通 

分 类 号：R725.1[医药卫生—儿科]